Glenmark Specialty S.A.

Quick facts

Phase 3 pipeline

• GMM-2 NS
  GMM-2 NS is a novel formulation designed to modulate immune or inflammatory pathways, though its exact mechanism requires further clinical characterization.
• GOM-NS
  GOM-NS is an investigational drug in phase 3 development by Glenmark Specialty S.A., but its specific mechanism of action is not publicly disclosed.
• GSP 301 NS
  GSP 301 NS is a nasal spray formulation designed to deliver its active pharmaceutical ingredient through the nasal mucosa for systemic or local therapeutic effect.
• GSP 301 Placebo NS pH 3.7
  This is a placebo formulation with no active pharmaceutical ingredient.
• GSP 301 Placebo NS pH 7.0
  This is a placebo formulation with no active pharmaceutical ingredient.
• Mometasone furoate NS · Immunology / Allergy / Rhinology
  Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune responses and decreasing inflammatory mediator release.
• Olopatadine HCl NS · Allergy / Immunology
  Olopatadine HCl is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the nasal cavity.

Phase 2 pipeline

• Spiriva® Respimat® inhalation spray

Phase 1 pipeline

• GRC 54276

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Glenmark Specialty S.A. portfolio CI brief
• Glenmark Specialty S.A. pipeline updates RSS